Bioton (LTS:0DTR) Stock Based Compensation: zł0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DTR Bioton SA LTS:0DTR
66 GF Score
Price zł3.43
GF Value zł4.24
! 3 Warning Signs
View Full Analysis

What is Bioton Stock Based Compensation?

Bioton LTS:0DTR 66 Stock Based Compensation is zł0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0DTR with a GF Score™ of 66/100 and a GF Value™ of zł4.24. The stock has 3 warning signs investors should review.

Bioton's Stock Based Compensation for the three months ended in Mar. 2026 was zł0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.0 Mil.

Bioton Stock Based Compensation Related Terms

Bioton Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Bioton's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioton Stock Based Compensation Chart

Bioton Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioton Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0DTR
66GF Score
Bioton SA LTS:0DTR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioton Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.0 Mil.

What does a Stock Based Compensation of zł0.0 Mil mean?
Bioton (LTS:0DTR) has a Stock Based Compensation of zł0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bioton and its competitors.
Is Bioton's Stock Based Compensation too high?
Bioton's current Stock Based Compensation is zł0.0 Mil. Overall, Bioton has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioton's Stock Based Compensation compare to VRTX and REGN?
Bioton's Stock Based Compensation of zł0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bioton and its competitors. Bioton's current Stock Based Compensation is zł0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioton stock overvalued right now?
Bioton (LTS:0DTR) has a current Stock Based Compensation of zł0.0 Mil. The stock's GF Value™ is zł4.24, compared to a current price of zł3.43 — trading 19.1% below its estimated fair value. The current Stock Based Compensation is zł0.0 Mil. Bioton's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Bioton (LTS:0DTR), the current Stock Based Compensation is zł0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioton (LTS:0DTR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioton stock appears to be undervalued. The current stock price of zł3.43 is trading 19.1% below its estimated GF Value™ of zł4.24.

Key valuation signals for LTS:0DTR:

  • Stock Based Compensation: zł0.0 Mil
  • GF Value™: zł4.24 vs. price of zł3.43 (19.1% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0DTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioton Business Description

Other Exchanges BIO:Poland7U5:Germany
Address Ul. Starościńska 5, Warszawa, POL, 02-516
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
66GF Score

Get the complete analysis for LTS:0DTR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.43
Price
zł4.24
GF Value